Pfizer announces good news about anti-Corona pills
Pfizer announced good news about its anti-coronavirus (Covid-19) tablet, saying that final analyzes show an efficacy of close to 90 percent in preventing hospitalizations and deaths in high-risk patients.
The latest data indicates that the drug retains its effectiveness against the rapidly spreading mutated Omicron of the Corona virus.
The company announced last month that its oral drug was about 89 percent effective in preventing hospitalizations and death when compared to a placebo (a similar tablet without an active ingredient), based on provisional results in about 1,200 people.
The data announced on Tuesday included a thousand more people.
No one in the trial who received Pfizer died, compared with 12 who received the placebo.
Pfizer also announced early results from a second clinical trial that revealed that the drug reduced hospital admission rates by about 70 percent in about 600 at risk adults.
There are currently no approved oral anti-Covid-19 drugs in the United States.
Pfizer said 180,000 doses of the drug could be ready for shipment this year, and it plans to produce at least 80 million in 2022.
Follow our latest local and sports news and the latest political and economic developments via Google news